← The Wire
LUNGNasdaq
Pulmonx Corp
Surgical & Medical Instruments & Apparatus · DE · CIK 1127537
Provides minimally invasive treatments for severe emphysema patients using the Zephyr Valve and related systems
$58M
Market cap
$1.33
Last close
+6.4%
1D
+4.7%
5D
665K
Volume
Price · last 39 sessions+0.0%
May 4L $1.25 · H $1.68Jun 29
92
Total filings
Jun 4, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 4, 202610-Q10-QMay 4, 20268-KResults of OperationsApr 29, 2026DEFA14ADEFA14AApr 22, 2026DEF 14ADEF 14AApr 22, 202610-K10-KMar 10, 20268-KMaterial Agreement · Agreement TerminatedMar 5, 20268-KResults of OperationsMar 4, 202610-Q10-QNov 12, 20258-KResults of OperationsNov 12, 20258-KExecutive Change · Results of OperationsOct 27, 202510-Q10-QAug 1, 20258-KResults of OperationsJul 30, 20258-KShareholder VoteMay 23, 202510-Q10-QMay 2, 20258-KResults of OperationsApr 30, 2025DEFA14ADEFA 14AApr 8, 2025DEF 14ADEF 14AApr 8, 202510-K10-KFeb 25, 20258-KResults of OperationsFeb 19, 202510-Q10-QNov 1, 20248-KResults of OperationsOct 30, 202410-Q10-QAug 2, 20248-KResults of OperationsJul 31, 20248-KMaterial AgreementMay 23, 20248-KShareholder VoteMay 17, 202410-Q10-QMay 3, 20248-KResults of OperationsMay 1, 2024DEFA14ADEFA14AApr 5, 2024DEF 14ADEF 14AApr 5, 20248-KExecutive Change · Company UpdateApr 2, 2024SC 13GPULMONX CORP.Feb 29, 202410-K10-KFeb 27, 20248-KResults of OperationsFeb 21, 20248-KExecutive Change · Company UpdateFeb 21, 2024SC 13GSC 13GFeb 9, 202410-Q10-QNov 3, 20238-KResults of OperationsOct 30, 20238-KExecutive Change · Results of OperationsOct 10, 202310-Q10-QAug 4, 20238-KResults of OperationsAug 2, 20238-KShareholder VoteMay 18, 202310-Q10-QMay 8, 20238-KResults of OperationsMay 2, 2023DEFA14ADEFA14AApr 4, 2023DEF 14ADEF 14AApr 4, 202310-K10-KMar 1, 20238-KResults of Operations · New Debt / ObligationFeb 22, 2023SC 13GSC 13GFeb 13, 2023SC 13GMS INITIALFeb 10, 2023SC 13GSCHEDULE 13GJan 4, 202310-Q10-QNov 8, 20228-KMaterial Agreement · Results of OperationsNov 3, 202210-Q10-QAug 8, 20228-KResults of OperationsAug 2, 20228-KShareholder VoteMay 27, 2022SC 13GSC 13GMay 25, 202210-Q10-QMay 9, 20228-KResults of OperationsMay 3, 2022DEFA14ADEFA14AApr 15, 2022DEF 14ADEF 14AApr 15, 202210-K10-KMar 1, 20228-K/AResults of OperationsFeb 25, 20228-KResults of OperationsFeb 23, 2022SC 13GSEC SCHEDULE 13GFeb 11, 2022SC 13GCHAMPLAIN 13G TICKER LUNGFeb 11, 2022SC 13GSCHEDULE 13GFeb 10, 2022SC 13GSC 13GFeb 4, 202210-Q10-QNov 9, 20218-KResults of OperationsNov 2, 202110-Q10-QAug 10, 20218-KResults of OperationsAug 3, 20218-KExecutive ChangeAug 2, 2021SC 13GSC 13GJul 16, 20218-KShareholder VoteMay 21, 202110-Q10-QMay 12, 20218-KResults of OperationsMay 4, 2021DEFA14ADEFA14AApr 9, 2021DEF 14ADEF 14AApr 9, 20218-KExecutive ChangeMar 24, 2021
Insider Activity
In the 90 days to Mar 2, 2026: 5 sold $187K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | French Glendon E. IiiPresident and CEO | Sell | 58,368 | $1.43 | $83K |
| Mar 2, 2026 | French Glendon E. IiiPresident and CEO | Sell | 6,737 | $1.43 | $10K |
| Mar 2, 2026 | Lehman David AaronGENERAL COUNSEL | Sell | 4,433 | $1.43 | $6K |
| Mar 2, 2026 | Radhakrishnan SrikanthChief Science &Techn. Officer | Sell | 4,198 | $1.43 | $6K |
| Mar 2, 2026 | Lehman David AaronGENERAL COUNSEL | Sell | 4,051 | $1.43 | $6K |
| Mar 2, 2026 | Radhakrishnan SrikanthChief Science &Techn. Officer | Sell | 3,068 | $1.43 | $4K |
| Mar 2, 2026 | Rose Geoffrey BeranCHIEF COMMERCIAL OFFICER | Sell | 2,911 | $1.43 | $4K |
| Mar 2, 2026 | French Glendon E. IiiPresident and CEO | Sell | 2,708 | $1.43 | $4K |
| Mar 2, 2026 | Lehman David AaronGENERAL COUNSEL | Sell | 2,590 | $1.43 | $4K |
| Mar 2, 2026 | Radhakrishnan SrikanthChief Science &Techn. Officer | Sell | 2,461 | $1.43 | $4K |
| Mar 2, 2026 | Rose Geoffrey BeranCHIEF COMMERCIAL OFFICER | Sell | 2,125 | $1.43 | $3K |
| Mar 2, 2026 | Rose Geoffrey BeranCHIEF COMMERCIAL OFFICER | Sell | 1,861 | $1.43 | $3K |
| Mar 2, 2026 | Lehman David AaronGENERAL COUNSEL | Sell | 1,163 | $1.43 | $2K |
| Mar 2, 2026 | Rose Geoffrey BeranCHIEF COMMERCIAL OFFICER | Sell | 835 | $1.43 | $1K |
| Mar 2, 2026 | Radhakrishnan SrikanthChief Science &Techn. Officer | Sell | 756 | $1.43 | $1K |
| Dec 8, 2025 | Florin Daniel PDirector | Sell | 23,321 | $1.99 | $46K |
| Dec 1, 2025 | French Glendon E. IiiPresident and CEO | Sell | 6,281 | $1.57 | $10K |
| Dec 1, 2025 | Lehman David AaronGENERAL COUNSEL | Sell | 3,725 | $1.57 | $6K |
| Dec 1, 2025 | Lehman David AaronGENERAL COUNSEL | Sell | 3,401 | $1.57 | $5K |
| Dec 1, 2025 | French Glendon E. IiiPresident and CEO | Sell | 2,524 | $1.57 | $4K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance